Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Arena Pharmaceuticals ( ARNA) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 1.1%. By the end of trading, Arena Pharmaceuticals rose $0.09 (1.1%) to $8.14 on average volume. Throughout the day, 6,271,113 shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 5,476,700 shares. The stock ranged in a price between $7.82-$8.29 after having opened the day at $8.03 as compared to the previous trading day's close of $8.04. Other companies within the Health Care sector that increased today were: Vanguard Health Systems ( VHS), up 67.3%, Isis Pharmaceuticals ( ISIS), up 29.2%, USMD Holdings ( USMD), up 17.9% and Mela ( MELA), up 9.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $1.6 billion and is part of the drugs industry. Shares are down 10.8% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Arena Pharmaceuticals a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

On the negative front, Pingtan Marine Enterprise ( PME), down 64.2%, Biostar Pharmaceuticals ( BSPM), down 12.2%, Allergan ( AGN), down 11.6% and Cell Therapeutics ( CTIC), down 10.7% , were all laggards within the health care sector with Novartis ( NVS) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Global Stocks Weaken as Trump Opens New Fronts in Global Trade War

Global Stocks Weaken as Trump Opens New Fronts in Global Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat